Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Suspended Phase 2 Interventional Accepts healthy volunteers

Department of Defense PTSD Adaptive Platform Trial - Master Protocol

ClinicalTrials.gov ID: NCT05422612

Public ClinicalTrials.gov record NCT05422612. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 11:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Multi-center, Multi-arm, Randomized, Placebo-controlled, Double-blind, Adaptive Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Potential Pharmacotherapeutic Interventions in Active-Duty Service Members, Veterans, and Non-Veteran Civilians With PTSD

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase 2 randomized, double-blinded, placebo-controlled study that will evaluate multiple potential pharmacotherapeutic interventions for PTSD utilizing an adaptive platform trial design. Participants are randomized among the available cohorts in the study and the resulting randomization enables sharing/pooling of control participants, where all interventions may be compared to a common control (placebo). The master protocol describes the default procedures and analyses for all cohorts; treatment-specific eligibility requirements, safety and efficacy procedures, or endpoints are described in the cohort-specific appendices and reflected in the intervention-specific clinicaltrials.gov records.

Study identification

NCT ID
NCT05422612
Recruitment status
Suspended
Study type
Interventional
Phase
Phase 2
Enrollment
800 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 1, 2023
Primary completion
Jun 30, 2028
Completion
Jun 30, 2029
Last update posted
Jun 29, 2026

2023 – 2029

United States locations

U.S. sites
9
U.S. states
9
U.S. cities
9
Facility City State ZIP Site status
Homestead Associates in Research, Inc. Miami Florida 33032
Advanced Discovery Research Atlanta Georgia 30318
Tripler Army Medical Center (TAMC) Tripler AMC Hawaii 96859
Cincinnati Veteran's Affairs Medical Center Fort Thomas Kentucky 41075
Walter Reed National Military Medical Center (WRNMC) Bethesda Maryland 20889-5632
Upstate Clinical Research Associates, LLC Williamsville New York 14221
Wilford Hall Ambulatory Surgical Center (WHASC) San Antonio Texas 78236
Alexander T. Augusta Military Medical Center (ATAMMC): Fort Belvoir Virginia 22060-5285
Madigan Army Medical Center Joint Base Lewis McChord Washington 98433

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05422612, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 29, 2026 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05422612 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →